Metastatic Non-small Cell Lung Cancer (NSCLC)

Oncology
1
Pipeline Programs
8
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
ABP 215Phase 31 trial
Active Trials
NCT04466917Withdrawn0Est. Nov 2022
GS
Gilead SciencesFOSTER CITY, CA
2 programs
data collectionN/A
data collectionN/A
DS
Daiichi SankyoChina - Shanghai
1 program
data collectionN/A
Regeneron
RegeneronTARRYTOWN, NY
1 program
data collectionN/A1 trial
Active Trials
NCT05423327Terminated5,311Est. Oct 2022
Bristol Myers Squibb
1 program
data collectionN/A
Takeda
TakedaTOKYO, Japan
1 program
data collectionN/A
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
data collectionN/A
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
data collectionN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AmgenABP 215
Regenerondata collection

Clinical Trials (2)

Total enrollment: 5,311 patients across 2 trials

A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer

Start: May 2021Est. completion: Nov 20220
Phase 3Withdrawn
NCT05423327Regenerondata collection

Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)

Start: Dec 2021Est. completion: Oct 20225,311 patients
N/ATerminated

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
8 companies competing in this space